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Gasdermin pores permeabilize mitochondria
to augment caspase-3 activation during apoptosis
and inﬂammasome activation
1234567890():,;

Corey Rogers1, Dan A. Erkes2, Alexandria Nardone1, Andrew E. Aplin2, Teresa Fernandes-Alnemri1 &
Emad S. Alnemri1

Gasdermin E (GSDME/DFNA5) cleavage by caspase-3 liberates the GSDME-N domain,
which mediates pyroptosis by forming pores in the plasma membrane. Here we show that
GSDME-N also permeabilizes the mitochondrial membrane, releasing cytochrome c and
activating the apoptosome. Cytochrome c release and caspase-3 activation in response to
intrinsic and extrinsic apoptotic stimuli are signiﬁcantly reduced in GSDME-deﬁcient cells
comparing with wild type cells. GSDME deﬁciency also accelerates cell growth in culture
and in a mouse model of melanoma. Phosphomimetic mutation of the highly conserved
phosphorylatable Thr6 residue of GSDME, inhibits its pore-forming activity, thus uncovering
a potential mechanism by which GSDME might be regulated. Like GSDME-N, inﬂammasomegenerated gasdermin D-N (GSDMD-N), can also permeabilize the mitochondria linking
inﬂammasome activation to downstream activation of the apoptosome. Collectively, our
results point to a role of gasdermin proteins in targeting the mitochondria to promote
cytochrome c release to augment the mitochondrial apoptotic pathway.
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poptosis is a form of programmed cell death (PCD) that
plays critical roles in embryonic development, maintenance and regulation of a healthy immune system, and
tumor suppression. It is initiated in cells by a diverse range of
physiological and pathological stimuli, which ultimately lead
to activation of the intrinsic or extrinsic apoptotic pathways1,2.
The intrinsic pathway is activated by internal stress arising from
stimuli such as DNA damage, viral infection, glucocorticoids, and
hypoxia leading to Bax/Bak-mediated pore formation on the
outer mitochondrial membrane, which facilitates the release of
proapoptotic proteins such as cytochrome c (Cyt c) and HtrA2/
Omi into the cytosol3,4. Cytosolic Cyt c binds to Apaf-1 (apoptotic protease activating factor-1), leading to the recruitment and
activation of procaspase-9. Active caspase-9 then cleaves and
activates procaspase-3/7, which in turn leads to cellular demise by
cleaving hundreds of different cellular substrates2.
The extrinsic pathway is activated when ligands such as
tumor necrosis factor-α (TNFα) bind to death receptors1,2. The
ensuing oligomerization of these receptors leads to recruitment
and activation of caspase-8, which in turn directly cleaves
procaspase-3 to mediate cellular dismantling. Interestingly, activation of this pathway can also activate the intrinsic pathway
when caspase-8 cleaves the cytosolic Bcl-2 (B-cell lymphoma 2)
family member Bid5,6. This cleavage generates a truncated fragment called tBid that translocates to the mitochondria where
it activates Bax/Bak pores to release cytochrome c and activate
the Apaf-1 apoptosome.
Pyroptosis is a necrotic form of PCD mediated by members of
the gasdermin superfamily, which include GSDMA, GSDMB,
GSDMC, GSDMD, and GSDME (or DFNA5)7–12. These proteins
have been recently shown to possess intrinsic necrotic activity in
their gasdermin-N domains that is normally masked by their
gasdermin-C domains9,12,13. Proteolytic cleavage between their
gasdermin-N and -C domains releases the inhibitory gasderminC domain allowing the necrotic gasdermin-N domain to translocate and form oligomers in the plasma membrane9,12–16. These
oligomers form membrane-spanning pores that allow for the
release of inﬂammatory molecules such as interleukin (IL)-1β, IL18, and high-mobility group box 1 (HMGB1) as well as osmotic
swelling leading to cytolysis7–9. Among the gasdermin proteins,
only GSDMD and GSDME are cleaved by caspases between their
gasdermin-N and -C domains to form membrane pores7–12.
GSDME is cleaved by caspase-3 to induce pyroptosis downstream
of apoptosis, whereas GSDMD is cleaved by inﬂammatory caspases to induce pyroptosis downstream of inﬂammasome activation. GSDMA, GSDMB, and GSDMC also possess poreforming gasdermin-N domains12, but none of them have been
shown to be cleaved in response to physiological or pathological
stimuli to form functional pores.
In addition to their necrotic activity, GSDMA, GSDMC,
GSDMD, and GSDME have all been proposed to possess tumor
suppressive activity, as their expression suppresses cell proliferation and colony formation in gastric and colorectal cancer
cell lines17–20. Furthermore, expression of GSDMA, GSDMC, and
GSDMD was found to be downregulated in primary esophageal
squamous cell carcinoma and gastric cancer tumors19, and
expression of GSDME has been shown to be downregulated
in breast, gastric, and colorectal cancers due to promoter
hypermethylation17,18,21,22. In addition, reduced GSDME
expression decreases sensitivity of cancer cell lines to etoposideinduced apoptosis, while its ectopic overexpression increases
their sensitivity23,24. Lastly, GSDME expression is regulated by
p5324, which is known to activate the transcription of numerous
tumor suppressors and activators of apoptosis.
While the necrotic activity of gasdermins has recently been
extensively characterized, their tumor suppressive activity is
2

much less characterized as tumor suppressors typically act
upstream of apoptotic caspase-3/7 to promote apoptosis. In this
study, we demonstrate that in addition to its pyroptotic activity,
GSDME augments caspase-3/7 activation and apoptotic cell death
by targeting the mitochondria and releasing Cyt c. We further
show that, like Bid, cleavage of GSDME by death receptor signaling bridges the extrinsic to the intrinsic apoptotic pathway.
This novel function also appears to be conserved in GSDMD as
its inﬂammasome-generated GSDMD-N domain is also capable
of targeting the mitochondria and activating caspase-3/7 downstream of inﬂammasome activation. Lastly, using an in vivo
mouse model of melanoma, we demonstrate that GSDME may
possess a bona ﬁde tumor suppressor activity as GSDMEdeﬁcient melanoma cells form and grow larger tumors than their
wild-type (WT) counterparts.
Results
GSDME regulates caspase-3 activation. GSDME functions
downstream of caspase-3 to switch apoptotic cell death to secondary necrotic/pyroptotic cell death9,11. To investigate whether
GSDME plays additional roles in the apoptotic program, we
studied its contribution to glucocorticoid-induced T-lymphoblastic leukemia cell killing25,26, because glucocorticoids have
been shown to up-regulate GSDME messenger RNA in the
human T-lymphoblastic leukemia cell line CEM-C727. Treatment
of CEM-C7 with the glucocorticoid triamcinolone acetonide (TA)
induces upregulation and processing of GSDME (Fig. 1a, 1st
panel), followed by induction of pyroptosis as measured by
propidium iodide (PI) uptake (Fig. 1c), and release of HMGB1
(Fig. 1a, 4th panel) and lactate dehydrogenase (LDH; Fig. 1b) into
the culture medium. Deletion of GSDME by CRISPR/Cas9
(clustered regularly interspaced short palindromic repeats/
CRISPR-associated protein 9) gene editing (Supplementary
Fig. 1a-c), compromised TA-induced pyroptosis in these cells
(Fig. 1c). Interestingly, deletion of GSDME also considerably
decreased the kinetics and magnitude of caspase-3 activation by
TA treatment (Fig. 1d, h). These effects were not speciﬁc to TA
treatment or to CEM-C7 cells but were also observed with other
apoptotic stimuli in CEM-C7 cells (Fig. 1e–h, Supplementary
Fig. 1d–f), and in other cell types such as immortalized bone
marrow-derived macrophages (iBMDMs) (Supplementary Fig. 2),
the murine melanoma cell line B16 (Supplementary Fig. 3), and
the murine thymoma cell line EG7-Ova (Supplementary Fig. 4).
Together, these results show that GSDME functions both
downstream of caspase-3 to induce pyroptosis and upstream of
caspase-3 to augment caspase-3 activation.
GSDME activity is potentially regulated by phosphorylation.
To investigate whether posttranslational modiﬁcations may affect
membrane targeting and killing activity of GSDME-N fragment,
we searched the PhosphositePlus Resource (https://www.
phosphosite.org) to identify all posttranslational phosphorylation sites in GSDME that were reported in high-throughput
studies using proteomic mass spectrometry. This revealed that
GSDME can be phosphorylated at multiple residues including
T6, S69, S113, S114, T117, and S252. We next generated glutamate (phosphomimetic) or alanine mutants of these residues,
and then measure their pyroptotic activity in HEK293T cells.
Only the phosphomimetic T6E mutation signiﬁcantly inhibited
GSDME pyroptotic activity, while the alanine mutation had no
effect (Fig. 2a–c, Supplementary Fig. 5a–e). As T6 has been shown
to be phosphorylated28, and is a highly conserved residue in
GSDME in all species examined (Supplementary Fig. 5f), it is
likely that phosphorylation of this site plays an important physiological function.
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Fig. 1 GSDME regulates caspase-3 activation and pyroptosis in CEM-C7 cells. a Immunoblots of GSDME, caspase-3, and β-actin in cell lysates (Lys), or
high-mobility group box 1 (HMGB1) released in culture media (media) of CEM-C7 cells untreated (UT) or triamcinolone acetonide (TA) treated for the
indicated times. b Cytotoxicity of TA as measured by lactate dehydrogenase (LDH) release in the culture supernatants of untreated (Untreated) or TAtreated (TA) CEM-C7 cells for the indicated times. c, d Propidium iodide (PI) uptake (c), and active caspase-3 staining (d–g) in wild-type (WT) and
GSDME-knockout (KO) CEM-C7 cells treated with TA (d), etoposide (e), ultraviolet (UV) (f), or serum starvation (g) as measured on the IncuCyte over
time. h Immunoblots of GSDME, caspase-3, and β-actin in combined cell lysates plus culture media of WT and GSDME-KO (KO) CEM-C7 cells untreated
(UT) or treated with TA, etoposide, serum starvation, or UV as indicated. Results are representative of at least three independent experiments performed
in duplicate or triplicate. Error bars represent standard deviation (S.D.). Student’s t-test, *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005, ******p <
0.0000005

We next used confocal microscopy and an in vitro oligomerization assay to examine the possibility that phosphorylation of
T6 inhibits plasma membrane targeting and/or oligomerization of
GSDME-N. Confocal microscopy revealed that GSDME-N T6E
still localizes to the plasma membrane like WT and GSDME-N
T6A but does not induce the necrotic swelling seen in cells
expressing WT or GSDME-N T6A (Fig. 2d). However, the
in vitro oligomerization assay showed that while WT GSDME-N
forms dimers and high-molecular weight oligomers when
incubated with heavy membrane fraction from HEK293T cells,
GSDME-N T6E mutant fails to do so (Fig. 2e and Supplementary
Fig. 6). These observations suggest that phosphorylation of T6
inhibits the pore-forming activity of GSDME-N by preventing its
dimerization/oligomerization in membranes and this might be a
critical regulatory mechanism to control the pyroptotic activity of

GSDME and perhaps other gasdermin proteins. Indeed, T8 of
GSDMA that corresponds to T6 in GSDME (supplementary
Fig. 7a) is phosphorylated in response to activation of the Plk1
kinase29. Our results show that like GSDME-N, the pyroptotic
activity of GSDMA-N is completely abolished by phosphomimetic mutation of T8 to glutamate (Supplementary Fig. 7c, d).
We next investigated the effect of T6 phosphorylation on the
kinetics of pyroptosis and caspase-3/7 activation in CEM-C7knockout (KO) cells, stably reconstituted with WT or T6E mutant
GSDME. As expected, cells expressing the T6E mutant GSDME
exhibited diminished pyroptosis compared to WT cells or cells
expressing WT GSDME in response to TA (Fig. 3a, e) or
ultraviolet (UV; Fig. 3c, f) treatment as measured by PI uptake or
release of HMGB1. The kinetics of PI uptake or HMGB1 release
in T6E-expressing cells were comparable to those observed in
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GSDME-KO cells, conﬁrming that T6 phosphorylation is critical
for the pyroptotic activity of GSDME. Interestingly, cells
expressing the T6E mutant also showed signiﬁcant reduction in
the kinetics and magnitude of caspase-3 activation in response to
TA (Fig. 3b, e) or UV (Fig. 3d, f) treatment. This was also evident
by reduced cleavage of the T6E GSDME mutant (Fig. 3e, f, 8th
lane) compared to WT GSDME (Fig. 3e, f, 6th lane). These results
indicate that the pore-forming activity of GSDME is not only
required for pyroptosis but also required to enhance the kinetics
and magnitude of caspase-3 activation in response to apoptotic
stimuli.
GSDME-N targets the mitochondria to release death proteins.
To elucidate how GSDME potentiates caspase-3 activation during
apoptosis, we investigated whether GSDME-N targets and permeabilizes the mitochondria to release apoptotic factors like
Cyt c and HtrA2/Omi protease using confocal microscopy and
biochemical analysis. Ectopic expression of GSDME-N-EGFP in

HeLa cells that stably express mCherry-tagged HtrA2 caused a
considerable reduction in the amount of mitochondrial HtrA2mCherry compared to neighboring cells that do not express
GSDME-N-EGFP or cells expressing full-length GSDME-EGFP
or EGFP alone (Fig. 4a). Of particular interest, we observed
release of mitochondrial HtrA2-mCherry in cells that did not yet
show morphological features of pyroptosis (Fig. 4a, top panel,
green arrows), suggesting that GSDME-N permeabilizes the outer
mitochondrial membrane before plasma membrane rupture.
In support of these observations, time-lapse live-cell imaging
of HeLa-HtrA2-mCherry cells after transfection with GSDME-NEGFP showed that expression of GSDME-N-EGFP induces
early release of HtrA2-mCherry from the mitochondria into the
cytosol before it ruptures the cell membrane (Supplementary
Fig. 8, and Supplementary Movie 1).
Supporting the observation that GSDME-N targets the
mitochondria, we observed overlap between GSDME-NEGFP puncta and MitoTracker Red-stained mitochondria in
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GSDME-N-EGFP-expressing HEK293T cells (Fig. 4b, upper
panels). Moreover, the MitoTracker Red signal was weaker in
areas that overlapped with GSDME-N-EGFP, which is consistent
with the ability of mitochondrial pore-forming proteins to
6

decrease mitochondrial membrane potential. The full-length
GSDME-EGFP showed cytosolic distribution and did not colocalize with MitoTracker red (Fig. 4b, lower panels), indicating
that cleavage of GSDME is necessary for mitochondrial targeting.
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To provide further support that the GSDME-N fragment targets
the mitochondria in cells undergoing apoptosis, we biochemically
fractionated TNFα plus actinomycin D (TNFα/actD)-treated
CEM-C7 cells. These experiments revealed that endogenous
GSDME-N indeed localizes to the mitochondrial fraction during
apoptosis (Supplementary Fig. 9).
To provide direct evidence that GSDME-N can permeabilize
the mitochondria to release death proteins, we incubated puriﬁed
mitochondria with S100 extracts from HEK293T cells deﬁcient in
GSDME expression or stably expressing GSDME-EGFP or
GSDME-T6E-EGFP in the presence of recombinant caspase-3.
Upon cleavage of GSDME by caspase-3, the generated WT
GSDME-N (Fig. 5a, 2nd lane), but not T6E GSDME-N mutant
(Fig. 5a, 3rd lane), strongly induced release and depletion of Cyt c
from the mitochondria (Fig. 5a, 2nd lane). Similar results were
obtained when puriﬁed mitochondria were incubated with
puriﬁed caspase-3-cleaved WT or T6E GSDME proteins (Fig. 5b).
Furthermore, we looked at the release of Cyt c in HEK293T after
transient expression of GSDME-N. As GSDME-N also forms
pores in the plasma membrane, we saw extensive release of Cyt c
into the culture media, accompanied by a depletion of
mitochondrial Cyt c (Fig. 5c, 2nd lane). No Cyt c release was
observed after expression of full-length GSDME or the GSDMEN T6E mutant (Fig. 5c, 1st and 3rd lanes). Cyt c release and
depletion of mitochondrial Cyt c was also seen after expression of
the known mitochondrial pore-forming protein Bax (Fig. 5c, 4th
lane), but because Bax does not permeabilize the plasma
membrane, Cyt c remained in the cytosol. We also observed that
generation of the GSDME-N fragment by ectopic expression of
active caspase-330 in GSDME-EGFP-expressing HEK293T cells
resulted in Cyt c release from the mitochondria into the culture
media (Fig. 5d, 2nd lane). No Cyt c release was observed after
expression of the catalytically inactive caspase-3 C285A mutant
(Fig. 5d, 1st lane), or after expression of either active or inactive
caspase-3 in cells that express the uncleavable GSDME-D270EEGFP (Fig. 5d, 3rd and 4th lanes), indicating that generation
of GSDME-N fragment by active caspase-3 is necessary for Cyt
c release. Consistent with the above observations, we saw that
UV or TNFα treatment induces more release and depletion of
Cyt c from the mitochondria in WT cells compared to GSDMEKO CEM-C7 cells (Figs. 5e and 6d), indicating that physiological
levels of GSDME-N can permeabilize the mitochondria.
Permeabilization of the mitochondrial membrane can also lead
to increased mitochondrial reactive oxygen species (ROS)
production31. Consistent with these observations, apoptotic
stimuli induced more ROS production in WT and GSDMEEGFP-reconstituted GSDME-KO CEM-C7 cells compared with
GSDME-KO and GSDME-T6E-EGFP-reconstituted GSDME-KO
CEM-C7 cells (Supplementary Fig. 10). Collectively, our data
indicate that in addition to its pyroptotic function, GSDME-N
can also function as a mitochondrial pore-forming protein that
contributes to mitochondrial permeabilization and Cyt c release
during apoptosis.
GSDME bridges extrinsic and intrinsic apoptotic pathways.
Activation of caspase-8 in the extrinsic death receptor signaling
complex can lead to both direct caspase-3 activation by caspase-8
(type I pathway) and indirect caspase-3 activation by a caspase8-generated truncated Bid (tBid)-mitochondria-apoptosome
ampliﬁcation loop (type II pathway)5,6,32–34. GSDME-N, like
tBid, might also function as a second ampliﬁcation loop in the
extrinsic pathway to potentiate caspase-3 activation. To test this
hypothesis we stimulated the extrinsic pathway in GSDMEexpressing and -deﬁcient CEM-C7 cells with TNFα in the presence of actD, or TAK1 kinase inhibitors 5Z-7-Oxozeaenol or
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Takinib, which have been shown to potentiate TNFα-induced cell
death35,36. Our results show that TNFα/actD, TNFα/5Z-7Oxozeaenol, or TNFα/Takinib treatment induces more pyroptosis
and caspase-3 activation in WT compared to GSDME-KO CEMC7 cells (Fig. 6a–c and Supplementary Fig. 11b-e). Reconstitution
of GSDME-KO cells with WT, but not T6E, GSDME restored
pyroptosis and caspase-3 activation to levels comparable to those
observed in WT cells (Fig. 6a–c). TNFα/actD stimulation also
caused GSDME cleavage and more Cyt c release and depletion
from the mitochondria in GSDME-expressing compared to
GSDME-KO CEM-C7 cells (Fig. 6c, d), suggesting that the
increased caspase-3 activation in WT GSDME-expressing compared to GSDME-KO cells is likely due to the ability of the
GSDME-N fragment to target the mitochondria to induce Cyt
c release.
Western blot analysis of the effect of TNFα/actD stimulation
on GSDME and Bid in CEM-C7 cells showed no difference in the
kinetics of GSDME and Bid cleavage (Supplementary Fig. 11a),
suggesting that the GSDME and Bid ampliﬁcation loops are
activated simultaneously. To evaluate the contribution of these
two loops to death receptor-induced cell death, we generated BidKO and GSDME/Bid-double knockout (DKO) CEM-C7 cell lines
by CRISPR/Cas9 gene editing (Supplementary Fig. 12a, b).
Deletion of Bid did not affect the pyroptotic function of GSDME
as Bid-KO cells still retained the ability to take up PI after TNFα/
actD treatment (Supplementary Fig. 12c). However, the kinetics
of caspase-3 activation in the Bid-KO cells was signiﬁcantly below
those observed in WT cells, but comparable to those observed in
GSDME-KO cells (Fig. 6e). Interestingly, combined deletion of
Bid and GSDME further reduced the kinetics of caspase-3
activation (Fig. 6e), suggesting that they function independently
of each other to amplify the mitochondrial pathway. Consistent
with this, GSDME/Bid-DKO cells showed considerably less
TNFα/actD-induced Cyt c release than that observed in either
Bid-KO or GSDME-KO (Fig. 6f). Taken together, our results
demonstrate that GSDME permeabilizes the mitochondria during
death receptor signaling, thus bridging activation of the extrinsic
and intrinsic apoptotic pathways.
GSDME cleavage forms a self-amplifying feed-forward loop.
The ability of GSDME-N to permeabilize the mitochondria and
enhance caspase-3 activation suggests that GSDME cleavage
generates a self-amplifying, positive feed-forward loop. According
to this model, the initially generated GSDME-N fragment releases
Cyt c from the mitochondria, which in turn activates the Apaf-1
apoptosome, thereby causing further caspase-3 activation and
cleavage of GSDME. Supporting this idea, GSDME-N fragment
but not full-length or the inactive GSDME-N T6E mutant can
activate caspase-3 when transiently expressed in 293T cells
(Fig. 7a, b). All cells showing microscopic features of GSDME-Nmediated pyroptosis (cellular swelling and rounding) were also
positive for caspase-3 staining (Supplementary Fig. 13a). Furthermore, WT GSDME-N fragment was only able to activate
caspase-3 in WT mouse embryonic ﬁbroblasts (MEFs) but not
Apaf-1-KO MEFs (Supplementary Fig. 13b), indicating that
GSDME-N-mediated caspase-3 activation is dependent on functional Apaf-1 apoptosome. Interestingly, when the GSDME-N
was transiently expressed in HEK293T cells that stably express
full-length WT GSDME-EGFP (293T-GSDME-EGFP cells),
activation of caspase-3 by the GSDME-N fragment led to processing of GSDME-EGFP to generate additional GSDME-N
fragments (Fig. 7c, 3rd lane). No additional GSDME-N fragments
were generated when the inactive GSDME-N T6E mutant or fulllength GSDME were transiently expressed in these cells or when
GSDME-N was transiently expressed in cells expressing the
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incubated with recombinant caspase-3, and S100 lysates from control (Ctrl) HEK293T cells or from HEK293T cells stably expressing wild-type (WT)
GSDME-EGFP (WT) or GSDME-T6E-EGFP (T6E). (Lys+casp-3): S100 lysates after incubation with caspase-3 and mitochondria followed by removal of
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for cytosolic extracts or lysates. Quantitative analyses of Cyt c release in (a–e) are shown in Supplementary Fig. 16. Results are representative of at least
three independent experiments

uncleavable GSDME-D270E mutant (293T-GSDME-D270EEGFP) (Fig. 7c, 7th lane), indicating that generation of additional
GSDME fragments by the transiently expressed GSDME-N is
dependent on caspase-3-mediated cleavage of full-length
8

GSDME. Consistent with these results, induction of apoptosis
in CEM-C7 cells that express the T6E mutant generates less
GSDME-N fragment compared with cells that express WT
GSDME (see Figs. 3e, f, and 6c, upper panels).
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The above mechanism might explain how the human deafnessassociated GSDME mutant induces cochlear cell death. Indeed,
transient expression of deafness-associated GSDME mutant in
293T cells induced pyroptosis, caspase-3 activation, and Cyt
c release from the mitochondria (Fig. 7d–f). Combined, our
results demonstrate that GSDME-N can initiate a self-amplifying
positive feed-forward loop via activation of the Apaf-1

apoptosome/caspase-3, which further cleaves full-length GSDME
to enhance pyroptosis.
Inﬂammasome-generated GSDMD-N activates caspase-3.
GSDMD is the mediator of pyroptosis downstream of canonical
and non-canonical inﬂammasomes7,8,10. Interestingly, activation
of the inﬂammasomes can also lead to activation of apoptotic
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caspase-3 and -737–40. To investigate whether GSDMD cleavage
downstream of non-canonical inﬂammasome activation contributes to caspase-3 activation, we measured the kinetics of
caspase-3 activation after transfection of WT, GSDMD-KO, or
ASC-KO iBMDMs with lipopolysaccharide (LPS)41. Remarkably,
GSDMD deﬁciency signiﬁcantly delayed and reduced the amount
10

of LPS-induced caspase-3 activation (Fig. 8a, b). However, ASC
deﬁciency had no notable effect, ruling out the involvement of
ASC-dependent inﬂammasomes in the observed caspase-3 activation (Fig. 8a). GSDMD deﬁciency, but not ASC deﬁciency,
also signiﬁcantly reduced LPS-induced pyroptosis (PI uptake)
and Cyt c release (Supplementary Fig. 14). These results indicate
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Fig. 8 GSDMD functions downstream of the inﬂammasome to activate caspase-3. a Active caspase-3 staining in PamCSK4-primed wild-type (WT),
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that GSDMD cleavage contributes to caspase-3 activation by the
non-canonical inﬂammasome.
To show that GSDMD-N fragment can directly induce Cyt c
release from the mitochondria and caspase-3 activation, we
transiently expressed it in 293T cells and examined Cyt c release
and caspase-3 activation. Similar to GSDME-N, expression of
GSDMD-N, but not full-length GSDMD, resulted in Cyt c release
and caspase-3 activation (Fig. 8c, d). Similar results were observed
with GSDMA-N fragment (Fig. 8d and Supplementary Fig. 7b),
indicating that mitochondrial targeting, Cyt c release, and
caspase-3 activation is a general mechanism employed by the
gasdermin proteins to potentiate apoptosis.
GSDME may have a tumor suppressor activity. Our results
show that deletion of GSDME from CEM-C7, iBMDM, and B16Ova cell lines increased their proliferative capacity (Fig. 9a–c).
In addition, deletion of GSDME in B16-Ova cells enhanced
their colony-forming ability after treatment with etoposide
(Supplementary Fig. 15), suggesting that GSDME expression
enhances overall cell death and reduces cell survival consistent
with previous observations18. To further test if GSDME possesses
a tumor suppressive activity in vivo, we utilized a mouse model of
melanoma whereby WT C57BL/6J were subcutaneously injected
with either WT or GSDME-KO B16-Ova melanoma cells and
tumor growth was monitored over time. Consistent with the
in vitro results, GSDME-KO tumors formed and grew to reach

sacriﬁcial threshold signiﬁcantly faster than those expressing
GSDME (Fig. 9d, e). These results suggest that GSDME possesses
a tumor suppressive activity which might be related to its ability
to induce pyroptosis and potentiate caspase-3 activation by
activating the mitochondrial apoptotic pathway.
Discussion
GSDME is believed to be a putative tumor suppressor17,18,20, but
how it prevents tumorigenesis and why it is downregulated in
many different cancer types has remained a mystery. In addition,
although GSDME has recently been shown to form pores in the
plasma membrane when cleaved by caspase-39,11, this function
occurs downstream of PCD pathways and does not explain its
tumor suppressive activity.
In this study, we demonstrated that GSDME augments the
intrinsic apoptotic pathway in cancer cells by forming pores in
the mitochondria and releasing critical proapoptotic factors such
as Cyt c and HtrA2. Confocal imaging of cells expressing
GSDME-N-EGFP and mitochondrial HtrA2-mCherry show loss
of HtrA2-mCherry from the mitochondria much earlier than
the onset of plasma membrane ballooning, suggesting that
GSDME-N may preferentially permeabilize the mitochondria
before causing plasma membrane rupture. This observation
might be explained by the fact that mitochondrial membranes
contain cardiolipins, and gasdermin-N domain of several
gasdermins including GSDME show strong preference for
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or GSDME-KO (n = 9 mice) B16-Ova cells. Mice were killed once tumors reached volumes greater than 450 mm3. e A representative image of early tumor
volume difference between WT and GSDME-KO tumors in mice. f A model representing how GSDMD and GSDME permeabilize the mitochondria
to release cytochrome c (Cyt c) and augment caspase-3 activation and apoptosis. Cell growth curve signiﬁcance was determined by Student’s t-test,
**p < 0.005, ***p < 0.0005. Tumor survival curve signiﬁcance was determined by log-rank test, *p < 0.05

binding to cardiolipin and forming pores in mitochondria-like
liposomes11–14. According to recent studies, gasdermin pores
form inner diameters ranging from 10 to 18 nm depending on
the lipid composition in which they insert themselves12,42. This
should allow for the release of proapoptotic molecules such as Cyt
c which has a diameter of ~3 nm43.
Our results demonstrated that GSDME augments apoptosis by
stimuli that activate both the intrinsic and extrinsic apoptotic
pathways (Fig. 9f). It ampliﬁes intrinsic pathway signals by
forming more pores in the mitochondria leading to enhanced Cyt
c release and apoptosome activation. Similarly, it acts in parallel
and in a manner analogous to Bid in the extrinsic pathway to
augment Cyt c release and apoptosome activation. The ability of
12

GSDME to augment apoptosis by targeting and permeabilizing
the mitochondria suggests that it functions in a manner analogous to proapoptotic Bcl-2 family members1,3, which might
explain its putative tumor suppressive activity. Indeed, our ﬁndings show that GSDME expression suppresses tumor cell growth
in vitro and delays tumor formation and growth in vivo.
Besides triggering cell death, mitochondrial permeabilization
has been reported to engage nuclear factor-κB anti-tumor signaling to cause tumor regression in vivo44. During transformation, developing tumor cells experience a variety of stresses such
as hyperproliferation, excessive DNA damage, decreased survival
factor signaling, and increased oncogene signaling that would
normally result in activation of the apoptotic program and their
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own demise45. In order to survive these stresses, tumor cells
downregulate or inactivate genes whose products permeabilize
the mitochondria, such as the proapoptotic Bcl-2 proteins45.
Interestingly, GSDME has also been reported to be downregulated in breast, gastric, and colorectal tumors17,18,21,22. This
may represent an advantageous adaptation for tumor survival by
reducing activation of intrinsic apoptosis and possibly anti-tumor
signaling. It remains to be seen if mice deﬁcient in GSDME are
more prone to developing cancer.
Previous studies demonstrated that expression of the gain-offunction mutant GSDME in HEK293T cells induces apoptosis as
evidenced by both ﬂipping of phosphatidylserine to the outer
leaﬂet and DNA fragmentation46. In addition, when expressed in
Saccharomyces cerevisiae, this mutant colocalizes with mitochondria and causes elevated levels of ROS, oxidative stress, and
cell death47,48. Moreover, other family members have also been
suggested to activate the apoptotic program through the mitochondria. GSDMA, for example, has been shown to induce
apoptosis in pit cells of the gastric epithelium during TGF-β
signaling, and the N terminus of GSDMA3 has been shown to
target the mitochondria via Hsp90 to induce oxidative stress and
mitochondrial permeability transition49,50. Our ﬁndings are
consistent with these reports and further provide more insights
into the mechanism of how gasdermin proteins can cause
apoptosis through permeabilizing the mitochondrial membrane.
Several reports have demonstrated the ability of the
inﬂammasome-mediated pyroptotic pathway to activate the
apoptotic pathway37,38,40. Our results provide a link between
these two pathways by showing that GSDMD-N generated by
inﬂammatory caspases targets the mitochondria to induce
caspase-3 activation and apoptosis. Consistent with our ﬁndings,
a previous study showed that upon activation of the noncanonical inﬂammasome in macrophages, GSDMD disrupts the
mitochondrial membrane potential and leads to mitochondrial
decay before rupture of the plasma membrane51. Interestingly,
recent studies have also shown that GSDMD and GSDME are
capable of directly lysing bacterial membranes11–13. The proapoptotic and bactericidal functions of these proteins could provide an enhanced innate immune response during infection by
not only directly killing bacteria, but also killing the host cells
harboring these pathogens. These mechanisms represent two
important ways that cells can use to prevent the spread of bacteria
during infection.
GSDME was discovered due to the ﬁnding that mutations in
intron 7 lead to the development of sensorineural hearing loss
due to exon 8 skipping which introduces a pre-mature stop codon
that results in the translation of a C-terminally truncated
protein52,53. As the gasdermin-C domain folds over and masks
the pyroptotic gasdermin-N domain, the absence of the
gasdermin-C domain in the GSDME hearing-loss mutant represents a gain-of-function mutation that unmasks its pore-forming
activity independent of cleavage by caspase-3. Indeed, our data
show that expression of this mutant is capable of releasing Cyt c
from the mitochondria, activating caspase-3, and forming pores
in the plasma membrane. GSDME is expressed in cochlear hair
cells, which have a limited ability to regenerate themselves, and
therefore cumulative mitochondrial damage caused by the unregulated activity of the mutant GSDME could result in a progressive decline in cochlear hair cell viability and function
eventually leading to complete hearing loss54. Why mutant
GSDME appears to only cause pathological damage to this speciﬁc tissue and not others could be a result of differences in
GSDME expression, or tissue-speciﬁc differences in alternative
splicing of exon 8 of GSDME.
Intriguingly, our data show that GSDME protein is upregulated
in response to stimulation with the glucocorticoid (GC) TA in T-
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lymphoblastic leukemia CEM-C7 cells resulting in induction of
pyroptosis and enhancement of caspase-3 activation. GCs are a
class of steroid hormones that have been proposed to modulate
several functions within the immune system ranging from positive and negative selection of thymocytes to thymocyte cell death
induced by systemic concentrations of GCs reached during stress
responses55,56. In addition, GCs are considered the cornerstone
for the treatment of lymphoid cancers because of their ability to
induce growth arrest and apoptosis in these cell types57. The
mechanism of GC-induced apoptosis is not fully established, but
it is now believed to be mediated in part by GC receptor-mediated
transcriptional induction of proapoptotic Bcl-2 homology 3
(BH3)-only proteins25. Proapoptotic BH3-only proteins induce
apoptosis by inhibiting anti-apoptotic Bcl-2 proteins such as
Bcl-2 and Bcl-xL or activating proapoptotic Bcl-2 proteins such
as Bax and Bak58,59. These interactions lead to oligomerization
of Bax/Bak and their permeabilization of the mitochondrial
membrane. Since GSDME is induced and cleaved during
glucocorticoid-induced apoptosis, it is therefore likely that
GSDME plays important physiological roles in determining the
fate of developing thymocytes, the progression of lymphoproliferative disorders, or immune responses to stress. Thus, expression of GSDME in lymphoid malignancies might be an important
determining factor in their response to glucocorticoid treatment.
A number of high-throughput mass spectrometric studies
identiﬁed critical residues in gasdermins that are phosphorylated
by cellular kinases, suggesting that these posttranslational modiﬁcations may regulate gasdermin protein activities. Two of these
residues, T6 of GSDME and T8 of GSDMA, are highly conserved
in all species. Indeed, our studies revealed that phosphorylation
of T6 in GSDME or T8 in GSDMA appears to be an important
regulatory mechanism to inhibit their mitochondria- and plasma
membrane-pore-forming functions. The kinases responsible for
direct phosphorylation of these residues have not yet been
characterized, but one study has shown that activation of the
serine/threonine kinase PLK1 (polo-like kinase 1) induces phosphorylation of many cellular proteins including GSDMA29. PLK1
is a proto-oncogene and an important regulator of the G2/M
transition during cell cycle progression. Pharmacological inhibition or small interfering RNA-mediated depletion of PLK1 in
cancer cells results in activation of the apoptotic pathway60,61.
If PLK1 can directly or indirectly phosphorylate gasdermin
family members, then this may inhibit their pore-forming activity
during mitosis or during oncogenesis to prevent cell death.
Recently, a 3.8 Å cryo-electron microscopy structure of the
GSDMA3 pore was solved by Ruan et al.42, demonstrating that a
27-fold symmetry pore is formed in lipid bilayers. Interestingly,
they observed that helix α1 of GSDMA3 monomers juxtapose
end-on through hydrogen bonding and hydrophobic interactions
in the oligomerized pore conformation. The structure also
revealed that α1 is important for oligomerization. Speciﬁcally, α1
makes contact at oligomerization interface II with adjacent
GSDMA3-N monomers to stabilize pore formation. As our
GSDME-T6E mutant still retains its ability to localize to the
plasma membrane (Fig. 2d), it is likely that phosphorylation of
GSDME T6 or the equivalent GSDMA3 T8 residue introduces
a negative charge that pushes α1 away from the beta-barrel
domain and disrupts the oligomerization interface II. Indeed, our
results demonstrated that phosphomimetic mutation of T6E
of GSDME inhibits its dimerization/oligomerization and poreforming and apoptotic activities
In conclusion, our work provides a conceptual advance in
understanding the function of GSDME in the apoptotic program
and tumor suppression. We have demonstrated that GSDME is
an important and novel mitochondrial pore-forming protein that
augments activation of the apoptotic pathway by releasing Cyt
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c from the mitochondria and activating the intrinsic apoptotic
pathway. This function appears to be shared by other family
members such as GSDMD, which too can activate the intrinsic
pathway downstream of inﬂammasome activation. Future studies
should focus on how GSDME can be exploited to predict the
responsiveness of cancers to different therapeutics (i.e., lymphoid
cancers to glucocorticoid treatment) and to design novel drugs
that target this pathway.
Methods
Antibodies and reagents. T7˙Tag monoclonal antibody horseradish peroxidase
(HRP)-conjugate (Cat. No. 69048) was from Novagen. Anti-DFNA5/GSDME
(Cat. No. ab215191), anti-GSDMD (Cat. No. ab209845), anti-GFP-HRP (Cat. No.
ab6663), anti-HMGB1 (Cat. No. ab18256), and anti-VDAC1 (Cat. No. ab154856)
were from Abcam. Caspase-3 (Cat. No. 9662) and Cox IV (Cat. No. 4844) were
from Cell Signaling Technologies. Anti-Bax (Cat. No. sc-930) and anti-GSDMA
(Cat. No. sc-376318) were from Santa Cruz. Anti-cytochrome c (Cat. No. 556433)
was from BD Biosciences. Anti-tubulin (Cat. No. CP06) was from Oncogene. All
antibodies for western blot analyses were used at 1:1000 dilution except for anti-βactin which was used at 1:10,000. Monoclonal anti-β-actin (Cat. No. A5441),
propidium iodide (Cat. No. P-4170), triamcinolone acetonide (Cat. No. T-6501),
5Z-7-Oxozeaenol (Cat. No. O9890), and actinomycin D were obtained from Sigma
Aldrich. TNFα (Cat. No. 210-TA-020) and anti-caspase-8 antibody (Cat. No.
AF1650) were obtained from R&D Systems (Cat. No. 210-TA-020). Etoposide (Cat.
No. A1971) was obtained from ApexBio. CytoTox96 LDH release kit (Cat No.
G1780) was from Promega. In-Fusion HD Cloning Plus (Cat. No. 638910) was
obtained from Takara Clontech. IncuCyte® Caspase-3/7 Green and Red Apoptosis
Assay Reagents (Cat. Nos. 4440 and 4704) were obtained from Essen BioScience.
MitoTracker Red CMXRos (Cat. No. M7512) and Hoechst (Cat. No. I34406) were
obtained from Invitrogen. DSS (Cat. No. 21555) and CellROXTM Deep Red
Reagent (Cat. No. C10422) were obtained from Thermo Scientiﬁc. Ultrapure LPS
and Pam3CSK4 were obtained from InvivoGen.
Cell culture and treatments. CEM-C7 (a derivative of CCRF-CEM, ATCC® CCL119™)62, B16-Ova (a derivative of B16F0, ATCC® CRL-6322™)63, and E.G7-Ova
(ATCC® CRL-2113™) cells were cultured in RMPI 1640 medium (Gibco) supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES pH 7.0 (Invitrogen),
100 U/mL penicillin and streptomycin, 1 mM sodium pyruvate (Cellgro), 2 mM
L-glutamine, and 0.1% 2-mercaptoethanol (Gibco). Bone marrow-derived cells
were harvested from the femurs of WT (C57BL/6) and knockout mice and differentiated into BMDMs by culturing in Dulbecco's modiﬁed Eagle's medium
(DMEM; Gibco) supplemented with 10% FBS, 10 mM HEPES pH 7.0 (Invitrogen),
100 U/mL penicillin and streptomycin (complete DMEM), and 20%
L929 supernatants in 10 cm dishes at 37 °C with 5% CO2 for 5–6 days. Immortalized BMDMs were generated by transformation of primary BMDMs with
J2-CRE retrovirus64. The 293T cells were cultured in DMEM/F12 (Gibco) supplemented with 10% FBS, 10 mM HEPES pH 7.0 (Invitrogen), and 100 U/mL
penicillin and streptomycin. HeLa HtrA2-mCherry cells were cultured in complete
DMEM and WT and Apaf-1-KO MEFs were cultured in complete DMEM supplemented with 2 mM L-glutamine. For caspase-3/7 activation and PI uptake
kinetic experiments, 1 × 105 iBMDMs or B16-Ova cells were seeded in 96-well
plates overnight or 1 × 105 CEM-C7 or E.G7-Ova were seeded the same day. On
the day of treatment, 1:1000 dilution of caspase-3/7 apoptosis reagent, 5 µM
CellROXTM Deep Red Reagent, or 1.5 µM propidium iodide with or without
1 µg/mL actinomycin D or 125 nM 5Z-7-Oxozeaenol, and 1 ng/mL TNFα,
10 µg/mL triamcinolone acetonide, or 150 µM etoposide was added to cells or cells
were exposed to 22 mJ/cm2 UV irradiation in a UV Stratalinker® 1800. Plates were
placed in the IncuCyte® S3 Live Cell Analysis System and imaged at 20× magniﬁcation. Signal percentage was calculated with the formula (percent red conﬂuence/
percent phase conﬂuence) × 100. Unless otherwise indicated, background signal
from untreated samples was subtracted from treated sample signal.
For transfection experiments, 293T cells were seeded overnight in 6-well plates
at a density of 6 × 105 cells per well. The next day, cells were transfected with 500
ng of plasmid DNA using Lipofectamine 2000 (7 μL/mL) as per the manufacturer’s
protocol (Invitrogen) in 1 mL of Opti-MEM per well. For Incucyte imaging, 1:1000
dilution of caspase-3/7 apoptosis reagent or 1.5 µM propidium iodide was added to
cells after transfection and the plates were placed in the IncuCyte® S3 Live Cell
Analysis System and imaged at 20× magniﬁcation. The culture supernatants and
cells were collected 18–24 h later for western blot analysis.
GSDME oligomerization. Stable 293T, 293T GSDME-EGFP, or 293T GSDMET6E-EGFP cell pellets were resuspended in 2.5× volume of Buffer A (250 mM
sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA,
1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl ﬂuoride, pH 7.5) and left on ice
for 15 min. Cells were lysed by passing through a syringe (30×) using a 26 G needle.
The lysates were centrifuged at 800 × g for 10 min at 4 °C in a refrigerated
Eppendorf 5417 R centrifuge. The 293T supernatant was collected and further
centrifuged at 7000 × g for 10 min to pellet heavy membranes. The resulting pellet
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was washed with Buffer A, divided into 2 tubes, and spun again. GSDME-EGFP
and GSDME-T6E-EGFP supernatants were further centrifuged at 100,000 × g for
10 min at 4 °C and the resulting supernatants were designated S100 lysates. To
generate GSDME cleavage, 100 µL reactions were set up with recombinant caspase3 and incubated at 37 °C for 1.5 h. To facilitate oligomerization, reactions were then
added to the heavy membrane pellet from 293Ts and incubated at 37 °C for an
additional 30 min. Reactions were centrifuged at 7000 × g for 10 min. Pellets were
washed in Buffer A, centrifuged again, and resuspended in 100 µL Buffer A. Then,
20 µL of the resuspended material was incubated with 3 mg/mL disuccinimidyl
suberate (DSS) for 30 min at room temperature, and 20 µL of 2× Laemmli
buffer with 2-mercaptoethanol (2-ME) was added to quench the reaction. The 2×
Laemmli buffer containing or not containing 2-ME was also added to two separate
20 µL suspensions, and these reactions were analyzed by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE).
Generation of CRISPR/Cas9 knockout cell lines. The CRISPR design tools at
MIT (http://crispr.mit.edu) or Benchling (https://benchling.com) were used to
identify candidate single-guide RNA (sgRNA) sequences. Sequences targeting
human GSDME exon 1 (5’-AGTACCAGTTTTTATCCCTC-3’ and 5’-TCAC
CCTTGGCGATGTACTC-3’) or exon 3 (5’-CGTAGAGAGCCAGTCTTCAT-3’),
murine GSDME exon 3 (5’-GTGTGAGAACCATAAGAGCG-3’ and 5’-GGG
CTATTGGGACAGTCGTG-3’), and human Bid exon 2 (5’-CAACAACG
GTTCCAGCCTCA-3’ and 5’-CAGGGATGAGTGCATCACAA-3’) were cloned
into lentiCRISPRv2GFP vector (Addgene) containing Cas9 fused to EGFP. Next,
5 µg lentiCRISPRv2GFP sgRNA plasmids were cotransfected with 3.75 µg psPAX2
and 2.5 µg VSVg plasmids (Addgene) using 25 µL Lipofectamine 2000 to 2 × 106
293Ts seeded the day before. At 72 h after transfection, media were collected and
concentrated overnight using Lenti-X Concentrator (Takara Cat. No. 631232) as
per the manufacturer’s protocol. Infected 1 × 106 CEM-C7 or 2.5 × 104 B16-Ova
cells/mL were plated in a 12-well plate with concentrated lentivirus. Cells were then
enriched for Cas9-EGFP expression by ﬂow cytometry and single cells were then
isolated and screened by western blot analysis for protein expression. Sequencing
was performed on PCR-ampliﬁed genomic DNA encompassing the sgRNA targeting sequences.
Generation of constructs and stable cell lines. GSDMA, GSDMD, and GSDME
constructs were made in pcDNA3, pEGFPN1, or pMSCVpuro EGFPN1 vectors
using the In-Fusion PCR cloning kit with appropriate PCR primers and full-length
human GSDMA, human or mouse GSDME, or mouse GSDMD complementary
DNAs (cDNAs). The human GSDMA cDNA was obtained from TransOMIC
(MGC premier cDNA clone for GSDMA–BC109197, Cat. No. TCH1003), the
human GSDME cDNA was obtained from TransOMIC (MGC premier
cDNA clone for GSDME–BC125065, Cat. No. TCH1003), the mouse GSDME
cDNA was obtained from TransOMIC (MGC premier cDNA clone for
GSDME–BC132303, Cat. No. TCM1003), and the mouse GSDMD cDNA was
obtained from Dharmacon (MGC Mouse GSDMD cDNA clone ID 4194837, Cat.
No. MMM1013–202765078). Stable GSDME-EGFP and GSDME-D270E-EGFP
cell lines were generated by transfecting pEGFPN1-GSDME or pEGFPN1GSDME-D270E plasmids followed by multiple cell sorting over a period of
1 month by ﬂow cytometry.
LDH release assay. Pyroptosis was quantitated by assaying the activity of LDH
released into cell culture supernatants after various treatments and transfections
using the CytoTox96 LDH release kit (Promega) according to the manufacturer’s
protocol. The LDH activity in the culture supernatant was expressed as a percentage of total LDH in the cell lysate.
Immunoblot analysis. CEM-C7, E.G7-Ova, iBMDM, and 293T cells were lysed in
buffer containing 50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% NP-40,
and protease inhibitors and clariﬁed by spinning at 14,000 RPM for 10 min at 4 °C
in an Eppendorf tabletop 5417R refrigerated microcentrifuge. B16-Ova cells were
lysed by adding 2× Laemmli buffer. Cell lysates were fractionated by SDS–PAGE
and then transferred to polyvinylidene diﬂuoride (PVDF) membranes (Bio-Rad).
To examine HMGB1 release, cell culture supernatants were precipitated by
methanol/chloroform method64,65. Brieﬂy, culture media were spun at 2000 RPM
for 5 min to pellet cells and cell debris. Supernatants were transferred to a fresh
tube and proteins were precipitated by the addition of an equal volume of methanol
and 0.25 volumes of chloroform to each sample followed by centrifugation at
12,000 RPM for 10 min. The upper phase was discarded and the same volume
of methanol was again added to the interphase of each sample followed by
centrifugation for 5 min at 14,000 RPM. The resulting protein pellets were dried
at room temperature, resuspended in 2× Laemmli buffer, and boiled for 10 min
at 99 °C until dissolved. The resuspended proteins were fractionated on 12%
SDS–PAGE followed by electroblotting onto PVDF membranes. Blots were probed
with appropriate antibodies.
To examine total cleaved caspase-3 after treatment, cells were ﬁrst lysed in
their culture media by adding Triton X-100 to each well to a ﬁnal concentration of
0.8%. Proteins were precipitated by methanol/chloroform extraction and prepared
for western blot analysis as described above. Full size images are presented in
Supplementary Figs. 20–33.
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Confocal microscopy. 4 × 105 293T or 2 × 105 HeLa HtrA2-mCherry cells were
seeded on 35 mm cover glass-bottom culture dishes and allowed to attach for 24 h.
Cells were transfected with constructs for different GSDME mutants for 18–24 h
using Lipofectamine 2000 and then stained with Hoechst 33342 and/or MitoTracker Red CMXRos for 30 min. Cells were observed using a Nikon A1R resonant
scanning confocal microscope (Bioimaging Shared Resource of the Kimmel Cancer
Center (NCI 5 P30 CA-56036)). Live-cell time course was performed by taking
images every 10 min for 7 h.
Cytochrome c release assay. After treatment or transfection, cells were collected
and washed in phosphate-buffered saline (PBS). Pellets were then resuspended in
5× volume of cytosolic extraction buffer (250 mM sucrose, 70 mM KCl, 137 mM
NaCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, 300 µg/mL digitonin, and protease
inhibitors) and incubated on ice for 5 min. Samples were centrifuged at 1000 × g at
4 °C for 5 min. The supernatant was collected and run as the cytosolic fraction.
Pellets were then resuspended in 5× volume of mitochondrial lysis buffer (50 mM
Tris, pH 7.4, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.2% Triton X-100, 0.3%
NP-40, and protease inhibitors) and incubated on ice for 10 min. Samples were
then spun at 10,000 × g at 4 °C for 10 min. The supernatant was collected and run
as the mitochondrial fraction. The culture media were also collected, precipitated
by methanol/chloroform as described above, and run as the media fraction.
GSDME-EGFP puriﬁcation and mitochondrial permeabilization assays.
GSDME-EGFP or GSDME-T6E-EGFP were puriﬁed on GFP-Trap Agarose beads
(Chromotek Cat. No. gta-20) according to the manufacturer’s protocol. Brieﬂy,
stable 293T GSDME-EGFP or GSDME-T6E-EGFP cells were lysed in 10 mM Tris,
pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 0.5% NP-40 supplemented with protease
inhibitors and spun at 20,000 × g for 10 min. Supernatant was collected and diluted
with 10 mM Tris, pH 7.5, 150 mM NaCl, and 0.5 mM EDTA. Dilutions were
rotated for 1 h at 4 °C with 50 µL GFP-Trap agarose beads followed by 3 washes
with dilution buffer. To elute GSDME-EGFP, beads were mixed with 50 µL 0.2 M
glycine, pH 2.5 for 30 s. After spinning, the supernatant was collected and neutralized with the addition of 5 µL 1 M Tris, pH 10.4.
Mitochondria were puriﬁed by resuspending 293T cells in 2.5× volume of buffer
A and incubating on ice for 15 min. The cells were lysed by syringing (30×) with
a 26 G needle. The lysates were centrifuged at 800 × g for 10 min at 4 °C in a
refrigerated Eppendorf 5417 R centrifuge. The 293T supernatant was collected and
further centrifuged at 7000 × g for 10 min to pellet mitochondria. Pellet was
resuspended in 2.5× volume of buffer A. The 20 µL reactions were set up with 1 or
5 µL puriﬁed GSDME-EGFP, 5 µL mitochondria, and recombinant caspase-3 and
incubated at 37 °C for 1 h. Reactions were spun at 7000 × g for 10 min. The
supernatant was collected, and the pellet was resuspended in 20 µL buffer A. Then,
2× Laemmeli buffer was added to each fraction and analyzed via western blot.
S100 mitochondria permeabilization experiments were performed by
resuspending stable 293T GSDME-EGFP or GSDME-T6E-EGFP cells in 2.5×
volume buffer A and incubating on ice for 15 min. The cells were lysed by syringing
(30×) with a 26 G needle. The lysates were centrifuged at 800 × g for 10 min.
Supernatants were collected and spun at 100,000 × g for 10 min. Then, 20 µL
reactions were set up by adding 5 µL mitochondria puriﬁed as described above to
14 µL S100 lysate and recombinant caspase-3. Reactions were incubated at 37 °C
for 1 h and spun at 7000 × g for 10 min. Fractions were then analyzed as above.

bucket rotor. The top of the 1 M sucrose layer containing plasma membrane
fraction and the interface between the 1 M and 1.5 M sucrose layers containing the
mitochondria fraction were collected, diluted to 0.25 M sucrose with a 5 mM TrisHCl and 1 mM EDTA solution. These diluted fractions were then centrifuged at
17,000 × g for 15 min at 4 °C. The resultant pellets were resuspended in equal
volumes of buffer A and analyzed by SDS–PAGE.
Colony formation assay. Colony formation was determined by Clonogenic
assay66. The 500 WT or GSDME-KO B16-Ova cells were seeded in a 6-well plate
and allowed to attach at 37 °C with 5% CO2 for 4 h. Cells were then treated with
500 nM etoposide for 4 h. Wells were washed, replaced with complete media, and
cells were grown for 7 days. Wells were imaged on the IncuCyte and colonies
containing >50 cells were counted.
Melanoma grafts. 3 × 105 WT or GSDME-KO B16 melanoma cells67 were injected
subcutaneously into the lower ﬂanks of C57BL/6 mice. Tumors volumes were
measured every 2–3 days using the formula V = 0.52 (length × width2). Animals
were killed when tumors reached volumes greater than 450 mm3. Survival curves
were generated from mice that formed tumors. All animal studies were performed
at Thomas Jefferson University and approved by Institutional Animal Care and
Use Committee, and comply with all relevant ethical regulations for animal testing
and research.
Statistics. Statistical analyses were made with Student’s t-test and log-rank test.

Data availability
The data that support the ﬁndings of this study are available from the corresponding
author on reasonable request. Source data for graphs presented in ﬁgures are provided in
the Source Data ﬁle.
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